Walsh Alex J, Cook Rebecca S, Skala Melissa C
Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee.
Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee.
J Nucl Med. 2017 Sep;58(9):1367-1372. doi: 10.2967/jnumed.117.192534. Epub 2017 Jun 6.
Primary tumor organoids are a robust model of individual human cancers and present a unique platform for patient-specific drug testing. Optical imaging is uniquely suited to assess organoid function and behavior because of its subcellular resolution, penetration depth through the entire organoid, and functional endpoints. Specifically, optical metabolic imaging (OMI) is highly sensitive to drug response in organoids, and OMI in tumor organoids correlates with primary tumor drug response. Therefore, an OMI organoid drug screen could enable accurate testing of drug response for individualized cancer treatment. The objective of this perspective is to introduce OMI and tumor organoids to a general audience in order to foster the adoption of these techniques in diverse clinical and laboratory settings.
原发性肿瘤类器官是个体人类癌症的强大模型，为患者特异性药物测试提供了一个独特的平台。光学成像因其亚细胞分辨率、穿透整个类器官的深度以及功能终点，特别适合评估类器官的功能和行为。具体而言，光学代谢成像（OMI）对类器官中的药物反应高度敏感，肿瘤类器官中的OMI与原发性肿瘤药物反应相关。因此，OMI类器官药物筛选能够实现对个体化癌症治疗药物反应的准确测试。本观点文章的目的是向广大读者介绍OMI和肿瘤类器官，以促进这些技术在不同临床和实验室环境中的应用。
